Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adial Pharmaceuticals, Inc. (ADIL)

0.2701   0 (0%) 11-28 09:49
Open: 0.27 Pre. Close: 0.2701
High: 0.2722 Low: 0.27
Volume: 14,688 Market Cap: 7(M)

Technical analysis

as of: 2022-11-28 9:46:07 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.33     One year: 0.37
Support: Support1: 0.23    Support2: 0.19
Resistance: Resistance1: 0.28    Resistance2: 0.31
Pivot: 0.28
Moving Average: MA(5): 0.28     MA(20): 0.28
MA(100): 0.53     MA(250): 1.35
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 51.8     %D(3): 54.4
RSI: RSI(14): 36.6
52-week: High: 3.04  Low: 0.23
Average Vol(K): 3-Month: 137 (K)  10-Days: 67 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADIL ] has closed above bottom band by 16.0%. Bollinger Bands are 88.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 76 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.29 - 0.29 0.29 - 0.29
Low: 0.27 - 0.27 0.27 - 0.27
Close: 0.28 - 0.28 0.28 - 0.28

Company Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Headline News

Mon, 28 Nov 2022
IPL 2023: 3 Teams That Can Target Adil Rashid In Auction - KhelTalk

Mon, 28 Nov 2022
Adil Najam | Greenbiz - GreenBiz

Fri, 25 Nov 2022
Adil Hussain: 'We All Need Lessons in Humility' - FILM COMPANION

Fri, 25 Nov 2022
Rakhi Sawant gets a kiss from boyfriend Adil Khan on her birthday, fans react - Hindustan Times

Wed, 23 Nov 2022
Family tribute to Adil Khan after teen 'shot' in Pakistan | Bradford Telegraph and Argus - Telegraph and Argus

Mon, 21 Nov 2022
Watch: When French team was evacuated from hotel during FIFA 2018 WC after Adil Rami used fire extinguisher at teammates - The Indian Express

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 27 (M)
Shares Float 23 (M)
% Held by Insiders 15.3 (%)
% Held by Institutions 7.1 (%)
Shares Short 148 (K)
Shares Short P.Month 175 (K)

Stock Financials

EPS -0.86
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.2
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -99.5
Return on Equity (ttm) -249
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.54
Qtrly Earnings Growth 0
Operating Cash Flow -12 (M)
Levered Free Cash Flow -9 (M)

Stock Valuations

PE Ratio -0.32
PEG Ratio 0
Price to Book value 1.36
Price to Sales 0
Price to Cash Flow -0.62

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.